Log in
NASDAQ:BMRN

BioMarin Pharmaceutical Competitors

$80.40
+2.25 (+2.88 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$78.37
Now: $80.40
$80.65
50-Day Range
$72.61
MA: $76.93
$79.88
52-Week Range
$68.25
Now: $80.40
$131.95
Volume766,776 shs
Average Volume1.77 million shs
Market Capitalization$14.60 billion
P/E Ratio18.40
Dividend YieldN/A
Beta0.69

Competitors

BioMarin Pharmaceutical (NASDAQ:BMRN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying BMRN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to BioMarin Pharmaceutical, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Volatility and Risk

Amgen has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Amgen and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
BioMarin Pharmaceutical45.74%4.34%2.84%

Analyst Ratings

This is a breakdown of recent recommendations for Amgen and BioMarin Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
BioMarin Pharmaceutical0101302.57

Amgen presently has a consensus price target of $254.08, indicating a potential upside of 13.02%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Amgen.

Earnings & Valuation

This table compares Amgen and BioMarin Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.60$7.84 billion$14.8215.17
BioMarin Pharmaceutical$1.70 billion8.56$-23,850,000.00$0.071,148.57

Amgen has higher revenue and earnings than BioMarin Pharmaceutical. Amgen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gilead Sciences (NASDAQ:GILD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Gilead Sciences and BioMarin Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.78
BioMarin Pharmaceutical$1.70 billion8.56$-23,850,000.00$0.071,148.57

Gilead Sciences has higher revenue and earnings than BioMarin Pharmaceutical. Gilead Sciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
BioMarin Pharmaceutical45.74%4.34%2.84%

Volatility and Risk

Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and BioMarin Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
BioMarin Pharmaceutical0101302.57

Gilead Sciences currently has a consensus price target of $76.1538, indicating a potential upside of 26.86%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Gilead Sciences.

Summary

BioMarin Pharmaceutical beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and BioMarin Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082212.77
BioMarin Pharmaceutical0101302.57

Vertex Pharmaceuticals currently has a consensus price target of $290.5862, indicating a potential upside of 28.18%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion14.16$1.18 billion$4.2952.85
BioMarin Pharmaceutical$1.70 billion8.56$-23,850,000.00$0.071,148.57

Vertex Pharmaceuticals has higher revenue and earnings than BioMarin Pharmaceutical. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
BioMarin Pharmaceutical45.74%4.34%2.84%

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats BioMarin Pharmaceutical on 12 of the 15 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for BioMarin Pharmaceutical and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical0101302.57
Regeneron Pharmaceuticals0101312.63

BioMarin Pharmaceutical currently has a consensus target price of $119.6667, suggesting a potential upside of 48.84%. Regeneron Pharmaceuticals has a consensus target price of $628.52, suggesting a potential upside of 22.27%. Given BioMarin Pharmaceutical's higher probable upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares BioMarin Pharmaceutical and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
Regeneron Pharmaceuticals37.30%26.71%19.39%

Insider & Institutional Ownership

89.4% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 2.2% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.56$-23,850,000.00$0.071,148.57
Regeneron Pharmaceuticals$7.86 billion6.98$2.12 billion$21.4723.94

Regeneron Pharmaceuticals has higher revenue and earnings than BioMarin Pharmaceutical. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioMarin Pharmaceutical has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats BioMarin Pharmaceutical on 9 of the 14 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

89.4% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 78.9% of Biogen shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

BioMarin Pharmaceutical has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BioMarin Pharmaceutical and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical0101302.57
Biogen5151302.24

BioMarin Pharmaceutical currently has a consensus target price of $119.6667, suggesting a potential upside of 48.84%. Biogen has a consensus target price of $305.9032, suggesting a potential upside of 25.48%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Profitability

This table compares BioMarin Pharmaceutical and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
Biogen35.63%51.00%23.54%

Valuation and Earnings

This table compares BioMarin Pharmaceutical and Biogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.56$-23,850,000.00$0.071,148.57
Biogen$14.38 billion2.61$5.89 billion$33.577.26

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

BioMarin Pharmaceutical beats Biogen on 8 of the 13 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Risk & Volatility

Seagen has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Seagen and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen-25.17%-18.32%-15.49%
BioMarin Pharmaceutical45.74%4.34%2.84%

Valuation & Earnings

This table compares Seagen and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million33.26$-158,650,000.00($1.33)-127.16
BioMarin Pharmaceutical$1.70 billion8.56$-23,850,000.00$0.071,148.57

BioMarin Pharmaceutical has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Seagen and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
BioMarin Pharmaceutical0101302.57

Seagen currently has a consensus price target of $176.75, indicating a potential upside of 4.51%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 48.84%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Seagen.

Insider & Institutional Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Seagen on 9 of the 15 factors compared between the two stocks.

pixel
Ad Oxford Club
The Time to Invest in 5G is NOW
AT&T has just become the first carrier to offer 5G coverage. Sprint's 5G network is live in Phoenix, New York City, Washington, D.C., and Los Angeles. T-Mobile has flipped the 5G switch in six cities... And Verizon has launched its 5G network in 13 cities. Nearly a decade in the making, 5G is finally here... And just ONE stock is your No. 1 chance to profit from the 5G revolution. Details here...

BioMarin Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.81+2.0%$130.88 billion$23.36 billion18.13Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$60.03+0.9%$75.25 billion$22.45 billion61.89Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$226.71+3.8%$58.95 billion$4.16 billion28.63
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$514.05+1.1%$54.85 billion$7.86 billion19.90
Biogen logo
BIIB
Biogen
2.0$243.78+0.8%$37.51 billion$14.38 billion8.07Analyst Revision
Seagen logo
SGEN
Seagen
1.4$169.12+2.2%$30.49 billion$916.71 million-112.00Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.0$123.83+0.7%$27.10 billion$4.99 billion28.93
Incyte logo
INCY
Incyte
1.5$83.25+2.5%$18.23 billion$2.16 billion-53.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$118.19+2.0%$17.78 billion$876.29 million-53.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.86+3.4%$15.09 billion$219.75 million-16.58Analyst Report
Analyst Revision
Repligen logo
RGEN
Repligen
1.4$186.99+3.0%$9.84 billion$270.24 million322.40
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.56+0.5%$8.93 billion$788.10 million45.29Analyst Downgrade
Novavax logo
NVAX
Novavax
1.8$125.69+18.4%$8.00 billion$18.66 million-45.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$51.13+1.7%$7.15 billion$1.12 billion106.52Insider Selling
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$23.24+2.1%$6.06 billion$182.24 million-20.21
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.54+0.3%$6.02 billion$1.45 billion13.92
Exelixis logo
EXEL
Exelixis
1.9$19.41+3.5%$6.02 billion$967.78 million40.44Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.23+2.3%$5.44 billion$195.99 million251.44Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$82.83+2.9%$4.39 billion$1.11 billion26.63
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$55.81+3.2%$3.86 billion$36.13 million-83.30
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+0.6%$3.83 billion$806.43 million-9.33
Alkermes logo
ALKS
Alkermes
1.3$18.50+0.4%$2.94 billion$1.17 billion-40.22
OPKO Health logo
OPK
OPKO Health
1.9$4.13+4.4%$2.77 billion$901.90 million-12.51
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.83+1.7%$1.89 billion$428.41 million17.14
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$119.11+6.0%$1.84 billionN/A-10.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.12+3.5%$1.43 billion$102.43 million-12.19
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$85.92+1.7%$1.38 billion$120.28 million-86.79
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.78+2.4%$1.34 billion$638.60 million-6.63
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.27+0.3%$1.23 billion$252 million-3.60
Innoviva logo
INVA
Innoviva
1.1$10.85+2.7%$1.10 billion$261.02 million5.54
Codexis logo
CDXS
Codexis
1.1$18.01+0.8%$1.07 billion$68.46 million-51.46
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.52+4.0%$1.04 billion$82.27 million-12.84Analyst Upgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$5.13+7.2%$905.78 million$48.83 million-6.75
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$22.75+4.4%$900.15 million$3.57 million-10.20
MannKind logo
MNKD
MannKind
0.9$3.08+4.2%$716.41 million$63.04 million-14.67
Agenus logo
AGEN
Agenus
1.6$3.71+5.4%$705.45 million$150.05 million-3.40
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.73+3.6%$690.21 million$109.33 million-3.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$12.41+2.4%$678.73 million$227.19 million5.94Analyst Downgrade
Heavy News Reporting
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.50+0.1%$650.03 million$38.19 million37.50
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.91+0.3%$623.59 million$150,000.00-4.16
Geron logo
GERN
Geron
1.4$1.87+3.2%$580.58 million$460,000.00-5.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.79+11.3%$527.73 million$35.22 million-3.50
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.11+5.8%$525.53 million$59.29 million-22.21
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.12+3.1%$455.67 million$22.27 million-4.47
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.76+6.7%$420.40 million$143.01 million-0.91
XOMA logo
XOMA
XOMA
1.4$32.05+1.9%$353.26 million$18.37 million-28.87Analyst Report
Insider Selling
Verastem logo
VSTM
Verastem
1.5$1.99+14.6%$337.85 million$17.46 million-1.41High Trading Volume
Unusual Options Activity
Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.59+1.2%$295.85 million$54.76 million-1.95
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.77+5.8%$259.56 million$36.63 million-3.18
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.